Disappointing cardiovascular study results had many investors fleeing a Canadian biotech stock Monday. Here’s some small stocks making big moves on Monday, September 30, 2019 (as of 4 pm EST):
Resverlogix Corp. (TSX:RVX), a Canadian biotech stock, plummeted 69% to $0.67 on Monday after announcing that BETonMACE did not meet the primary endpoint, which was the reduction in major adverse cardiovascular events, defined as cardiovascular death, non-fatal myocardial infarction and stroke.
As well, shares of Doubleview Capital Corp. (TSXV:DBV) gained 31% to $0.105 as the junior explorer said it is in the process of re-opening its Hat Camp in preparation for resumption of core drilling at the Hat gold-copper porphyry project in British Columbia.
Juggernaut Exploration Ltd. (TSXV:JUGR), meanwhile, reported results from the 2019 diamond drilling program on its Midas and Empire properties in British Columbia, which included 6.22 metres of 0.313 grams per tonne (g/t) gold. Juggernaut Exploration stock dropped 63% to $0.015 following the announcement.
Finally, Fire & Flower Inc. (TSX:FAF) shares eased 6% to $1.19 after the Horizons ETFs announced that it recently added Fire & Flower stock to its HMMJ portfolio.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Resverlogix Corp. (TSX:RVX), a Canadian biotech stock, plummeted 69% to $0.67 on Monday after announcing that BETonMACE did not meet the primary endpoint, which was the reduction in major adverse cardiovascular events, defined as cardiovascular death, non-fatal myocardial infarction and stroke.
